OncoMatch/Clinical Trials/NCT07317505
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Is NCT07317505 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies JMT108 for cancer.
Treatment: JMT108 — The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care
Participants...who are unresponsive or intolerant to all standard of care or have no standard of care available
Cannot have received: unapproved investigational drugs or treatments
Any other unapproved investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug (C1D1)
Cannot have received: chemotherapy
Exception: nitrosoureas or mitomycin C within 6 weeks
Chemotherapy...within 4 weeks prior to the first dose of the investigational drug, except in the following situations: 1. Nitrosoureas or mitomycin C within 6 weeks prior to the first dose
Cannot have received: radiotherapy
Radiotherapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: biological therapy
Biological therapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: endocrine therapy
Endocrine therapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: targeted therapy
Exception: oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives (whichever is longer)
Targeted therapy within 4 weeks prior to the first dose of the investigational drug, except in the following situations: 2. Use of oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer)
Cannot have received: immunotherapy
Immunotherapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: other anti-tumor therapies
Exception: herbal medicine/products with anti-tumor indications within 2 weeks
Other anti-tumor therapies within 4 weeks prior to the first dose of the investigational drug, except in the following situations: 3. Use of herbal medicine/products with anti-tumor indications within 2 weeks prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Carolina BioOncology Institute · Huntersville, North Carolina
- NEXT Dallas · Dallas, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07317505 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior unapproved investigational drugs or treatments, chemotherapy, radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify